The strong impact of the disturbance of LOX/LOXLs activity on CCL and heart performance [6,7,37] supports the interest of LOX/LOXLs-inhibitory therapies to improve cardiac remodeling and slow HF. The gene discussed is LOX; the disease is hydrops fetalis.